The necessity of anti-inflammatory drugs such as glucocorticoids has been
evident during the COVID-19 pandemic. Glucocorticoids, are the standard
therapy for the treatment of moderate and severe COVID-19 patients. However,
serious side effects limit the use of these drugs, and anti-inflammatory
drugs with better pharmacological properties are urgently required. Bile
acids are of interest, because of their anti-inflammatory and
immunomodulatory properties, facilitated through an unclear mechanism
involving trans-membrane and nuclear receptors. In this work, we screened
the binding activity of a number of bile acid derivatives, for the
ligand-binding domain of glucocorticoid receptor (GR-LBD), the most
important receptor for anti-inflammatory processes. Tested compounds include
oximes, lactones, lactams, tetrazoles, dienones, C-24 alcohols and cholic
acid amides. Cholic acid oxime, deoxycholic acid dienone, 3-keto-24-cholic
alcohol and cholic acid amide showed best binding affinities for GR-LBD
among tested compounds. The in silico molecular docking explanation is
provided. SAR analysis showed that expansion of B and C steroid rings or
attachment of heterocycle to C ring is not beneficial for binding; side
chain should contain hydrogen donor group; the GR-LBD tolerate well
different functionalities on C-3 position. These results provide valuable
information toward synthesis of the new glucocorticoids based on bile acids.